Please excuse the late reply.... good iterating post ajanta.These themes have been well aired by many here in the long and recent past..... self included....It is refreshing to re read them 2nd person in light of current exposure perspectives.
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
